Although treatment outcomes have improved, relapsed or refractory chronic lymphocytic leukemia (RRCLL) is still not curable with standard therapies and has a poor prognosis. Long-term data from patients with CLL who have received chimeric antigen receptor T-cell therapy against CD19 (CART-19) are now available.
Autoren
- Birke Dikken
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- De-escalation strategies
De-escalation strategies – less is more
- Pathogens in the brain
When infections trigger strokes
- Diabetes mellitus
Treatment of comorbidities in older people
- Pulmonary hypertension
PH and lung diseases
- Advanced NSCLC
MARIPOSA: Combination therapy as the new standard of care for EGFR-mutated NSCLC
- Atopic dermatitis and allergies Atopic dermatitis and allergies
Type 2 inflammation and other factors
- Idiopathic cholestasis
Genotype-phenotype correlations in PFIC
- Prevalence, pathogenesis and individual treatment strategies